GlassScriptPhysician profile
Ranjit S Grewal
NPI 1477561520
$4,421.90
in general payments reported to CMS, 2019-2025
41 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $427 · 2021: $613 · 2022: $746 · 2023: $665 · 2024: $577 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.89 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $532.47 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $516.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $423.59 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $248.52 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.94 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $161.57 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $125.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.33 | 2019-2025 | Xifaxan |
| Mylan Specialty L.P. | $93.99 | 2019-2023 | Yupelri |
| Currax Pharmaceuticals LLC | $79.16 | 2020-2023 | Nexletol |
| Arbor Pharmaceuticals, INC. | $76.01 | 2019-2022 | |
| Antares Pharma, INC. | $69.17 | 2020-2023 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $69.10 | 2019-2025 | |
| Tolmar, INC. | $66.53 | 2024-2025 | Jatenzo |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjit Grewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.